Saccharomyces boulardii I-745

Saccharomyces boulardii I-745 is a non-pathogenic yeast probiotic strain whose primary bioactive mechanism involves secreting a 54 kDa serine protease that degrades C. difficile toxins A and B. It colonizes the intestinal lumen transiently, modulating gut microbiota composition and reinforcing epithelial barrier integrity through upregulation of tight-junction proteins.

Origin & History

Saccharomyces boulardii CNCM I-745 is a non-pathogenic yeast probiotic originally isolated from tropical fruit peels (lychee and mangosteen) in the 1920s by French scientist Henri Boulard. It is produced through fermentation and lyophilization (freeze-drying) to maintain viability, with optimal growth at body temperature (37°C) and high acid tolerance for gastrointestinal survival.

Historical & Cultural Context

Isolated in the 1920s by Henri Boulard from Southeast Asian tropical fruits during dysentery outbreaks, S. boulardii became the first yeast probiotic studied in humans. While lacking deep roots in traditional medicine systems, it has been clinically developed since the 1950s for gastrointestinal disorders.

Health Benefits

• Reduces antibiotic-associated diarrhea duration and risk (strong evidence from meta-analyses and ESPGHAN guidelines)
• Shortens pediatric acute gastroenteritis by 13.4 hours compared to B. clausii (RCT n=317, P=0.04)
• Prevents recurrent C. difficile infections (recommended by clinical guidelines)
• Reduces H. pylori therapy side effects (guideline-supported)
• Decreases inflammatory markers IL-6 and TNF-α in sepsis models (animal evidence)

How It Works

S. boulardii I-745 secretes a 54 kDa serine protease that proteolytically cleaves C. difficile toxin A receptors on enterocytes and directly degrades toxins A and B, reducing mucosal inflammation. The strain also produces a 120 kDa phosphatase that dephosphorylates and inactivates lipopolysaccharide, dampening NF-κB-mediated pro-inflammatory cytokine release including TNF-α and IL-8. Additionally, it stimulates secretory IgA production and upregulates expression of tight-junction proteins such as claudin-1 and occludin, restoring intestinal barrier function disrupted by pathogens or antibiotics.

Scientific Research

A randomized trial in 317 children with acute diarrhea showed S. boulardii reduced diarrhea duration to 64.6 hours versus 78.0 hours with B. clausii (P=0.04). Over 130 trials exist supporting its use, with meta-analyses and ESPGHAN guidelines recommending it for antibiotic-associated diarrhea prevention. Review context suggests PMID reference PMC10621882.

Clinical Summary

Multiple meta-analyses, including a Cochrane review of over 30 RCTs, demonstrate that S. boulardii I-745 significantly reduces both the incidence and duration of antibiotic-associated diarrhea, with a number needed to treat of approximately 8. ESPGHAN guidelines recommend the strain for managing pediatric acute gastroenteritis, supported by an RCT of 317 children showing it shortens illness duration by 13.4 hours compared to B. clausii (P=0.04). For recurrent Clostridioides difficile infection, clinical guidelines endorse adjunctive use, with trials showing a reduction in recurrence rate from approximately 44.8% to 26.3% when combined with vancomycin or metronidazole. Evidence quality is strong for diarrhea endpoints but more limited for other indications such as IBS and Crohn's disease.

Nutritional Profile

Saccharomyces boulardii I-745 is a lyophilized probiotic yeast strain, not a traditional food ingredient, so its nutritional profile differs from conventional nutrients. Key compositional data: Protein content approximately 40-45% of dry cell weight (primarily structural and enzymatic proteins including proteases, saccharases, and heat shock proteins). Carbohydrates approximately 35-40% dry weight, dominated by cell wall beta-1,3/1,6-glucans (~30% of cell wall mass) and mannoproteins (~40% of cell wall), with intracellular trehalose serving as a cryoprotectant at ~15-20% of dry weight in lyophilized preparations. Lipids approximately 5-7% dry weight, primarily phospholipids (phosphatidylcholine, phosphatidylethanolamine) and ergosterol (provitamin D2 precursor, ~0.3-0.5% dry weight). Bioactive compounds: Secretory phosphatase (molecular weight ~63 kDa) capable of dephosphorylating bacterial endotoxins LPS and LTA; serine protease (~54 kDa) that cleaves C. difficile toxin A receptors and degrades cholera toxin; polyamines (spermidine, spermine) supporting intestinal epithelial repair. Micronutrient contributions per standard 250 mg capsule dose: B vitamins including thiamine (~0.8 mg equivalent), riboflavin (~0.3 mg), niacin (~3.5 mg), and folate (~15 mcg; bioavailability limited due to yeast matrix). Zinc present at approximately 0.4-0.6 mg per dose bound to metalloproteins. Selenium incorporated at ~2-4 mcg per dose depending on fermentation substrate. Fiber equivalent: beta-glucans from cell walls contribute approximately 40-60 mg per 250 mg dose; these are largely indigestible in the upper GI tract, acting as prebiotic-like substrates but with limited systemic carbohydrate contribution. Caloric contribution is negligible at therapeutic doses (~2-4 kcal per 250 mg capsule). Bioavailability note: S. boulardii I-745 is non-colonizing and transient; it is not absorbed systemically but exerts effects luminally. The lyophilized I-745 strain retains viability at room temperature and survives gastric acid better than many bacterial probiotics due to yeast cell wall architecture, with approximately 10^9 CFU per 250 mg dose reaching the intestinal lumen at ~60-70% viability post-gastric transit.

Preparation & Dosage

Clinically studied doses range from 250-500 mg (5-10 billion CFU) daily as lyophilized powder in capsules or sachets, typically for 5-7 days. Children often receive 250 mg twice daily. Standardization is to 2.5 x 10^9 CFU per 250 mg dose. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Lactobacillus rhamnosus GG, Prebiotics (FOS/Inulin), Zinc, Glutamine, Digestive Enzymes

Safety & Interactions

S. boulardii I-745 is generally well tolerated; the most commonly reported adverse effects are mild bloating and flatulence occurring in a small minority of users. Because it is a live yeast, it is contraindicated in immunocompromised individuals, patients with central venous catheters, and those with known yeast hypersensitivity due to rare but documented cases of fungemia. Concurrent use of oral antifungal agents (e.g., fluconazole, itraconazole) will reduce or eliminate viability of the probiotic and should be avoided. Safety data in pregnancy are limited to observational studies; use should be discussed with a healthcare provider before administration during pregnancy or lactation.